Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingPatterns of HIV/SIV Prevention and Control by Passive Antibody ImmunizationAnnulling a dangerous liaison: vaccination strategies against AIDS and tuberculosisComputational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity dataSurvivors Remorse: antibody-mediated protection against HIV-1.Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesControlling the HIV/AIDS epidemic: current status and global challengesLimited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamstersPost-infection immunodeficiency virus control by neutralizing antibodiesBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesReplicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralizationReplication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Broadly neutralizing antibodies suppress HIV in the persistent viral reservoirEnhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccinePotent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaqueHow can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.HIV transmission: closing all the doors.Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.Correction of a carboxyl terminal simian immunodeficiency virus Nef frameshift mutation restores virus replication in macaques.Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaquesHighly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.Breaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives.Neutralizing antibodies to HIV-1 induced by immunization.No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques
P2860
Q26782237-454208E2-3A0E-4E4C-BB2B-05F580458F68Q27675486-98ED3731-5161-4919-9F17-9161581B89FAQ28068018-0A3D35E0-D121-4B86-980C-9A3C369C5798Q28243702-423F3E91-64B2-43A9-899C-F096F5A44FDBQ28535583-F5912D1E-7FA8-4315-A9CC-E1278C1E14F0Q30238730-BEF37DCC-8132-4CB8-9DBD-C939586212A6Q30408097-CD5DABD8-6F14-43FC-93A3-660DE140CCC7Q30420558-3E826E24-84EE-4F1D-A4B3-E550AB49D94AQ31138949-A1F115D4-FD9B-437A-A3C4-2FA254837863Q33262275-65D7CD10-1752-4D9B-8013-6F42DFF52AC7Q33288264-E613FA58-8E50-46A1-8E93-7BFBF1DA66F2Q33780524-6401B9C1-AE88-4853-ADF3-4363E127FB93Q33887693-97A09962-E94E-4DC8-8129-2AADF24F2398Q33911935-69F7BDF5-BD77-4E42-A04E-89BEE79B2AB2Q33911986-15A7A4A3-18B0-4575-8D62-A9381DDDB72CQ33984182-7CE95EC9-82E0-4433-86E9-D2F8DF508ECEQ34053295-E9E05EB6-9764-4C18-ABF4-F5013D765981Q34150125-B5F7B482-9169-4383-BD6B-E6446312E5B5Q34180174-3E4BEC25-ADAE-41CD-85C1-F805907AF672Q34234905-2F7EBCD5-1003-4C25-94E7-0B1634EAB303Q34357068-9F6296CF-47DB-40EC-9935-D401AEBC461AQ34480617-6004376C-08FB-44E3-A4C2-4BA235F9F518Q34583552-09786A81-7870-4570-9FE9-31C7551F37C1Q34593860-50795DFD-9D94-4487-9E3B-A2B804FAA96EQ34637968-2C997B39-40C7-4268-81EE-C2DF6927A046Q35077483-3B381EA7-6BEF-4F66-A057-8FDA87163F92Q35200862-A1538E1D-8E2C-4730-A073-8A83FF1D793FQ35415717-F515372F-2B97-44A9-A397-DE869218F913Q35647701-15338AB2-C0B5-40D7-9BBE-E0C004CD7553Q35653703-7AA5486B-0051-431C-9B4E-E0A60DF0380DQ35666057-D49B403D-DB5E-4BE4-8748-6CB15CC96E46Q35743991-1CBFD930-050A-43A6-ACBE-65B09D439283Q35826784-AC7DB25B-2E19-4A90-9AD2-74FA3AF1DB77Q35955770-619844A6-2438-47A9-B3F2-8FBDA840FF73Q36161747-6378F59E-A695-47A6-9327-78D0EBCC2384Q36286484-E6AE7FF9-DDF5-4C44-888E-F852B72EB750Q36414891-D4C5F0A5-8E26-4D49-857E-EEAA0916DBE4Q36537806-C5F5B43A-31BE-43FE-BA93-579C47E7A719Q36603515-0FF58DD6-1792-42F4-8BDF-DA213A9D41CBQ36607322-2DCBF652-FF86-47EC-9326-4CD8D4EC5FF2
P2860
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@ast
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@en
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@nl
type
label
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@ast
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@en
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@nl
prefLabel
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@ast
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@en
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development.
@nl
P2093
P2860
P356
P1476
Transfer of neutralizing IgG t ...... for HIV-1 vaccine development
@en
P2093
Alicia Buckler-White
Charles Buckler
Malcolm A Martin
Olivia K Donau
Reza Sadjadpour
Ron J Plishka
Tatsuhiko Igarashi
Yoshiaki Nishimura
P2860
P304
15131-15136
P356
10.1073/PNAS.2436476100
P407
P577
2003-11-19T00:00:00Z